American Journal of Clinical Dermatology

, Volume 19, Issue 2, pp 223–235 | Cite as

Vitamin D and the Skin: An Update for Dermatologists

Review Article

Abstract

Vitamin D plays a key role in skeletal and cardiovascular disorders, cancers, central nervous system diseases, reproductive diseases, infections, and autoimmune and dermatological disorders. The two main sources of vitamin D are sun exposure and oral intake, including vitamin D supplementation and dietary intake. Multiple factors are linked to vitamin D status, such as Fitzpatrick skin type, sex, body mass index, physical activity, alcohol intake, and vitamin D receptor polymorphisms. Patients with photosensitive disorders tend to avoid sun exposure, and this practice, along with photoprotection, can put this category of patients at risk for vitamin D deficiency. Maintaining a vitamin D serum concentration within normal levels is warranted in atopic dermatitis, psoriasis, vitiligo, polymorphous light eruption, mycosis fungoides, alopecia areata, systemic lupus erythematosus, and melanoma patients. The potential determinants of vitamin D status, as well as the benefits and risks of vitamin D (with a special focus on the skin), will be discussed in this article.

Notes

Compliance with Ethical Standards

Conflict of interest

Elio Kechichian and Khaled Ezzedine have no conflicts of interest to declare.

Funding

No funding was received for the preparation of this review.

References

  1. 1.
    Wharton B, Bishop N. Rickets. The Lancet. 2003;362:1389–400.CrossRefGoogle Scholar
  2. 2.
    Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr. 2005;94:483–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Boucher BJ. Inadequate vitamin D status: does it contribute to the disorders comprising syndrome “X”? Br J Nutr. 1998;79:315–27.PubMedCrossRefGoogle Scholar
  4. 4.
    Grant WB, Garland CF, Holick MF. Comparisons of estimated economic burdens due to insufficient solar ultraviolet irradiance and vitamin D and excess solar UV irradiance for the United States. Photochem Photobiol. 2005;81:1276–86.PubMedCrossRefGoogle Scholar
  5. 5.
    Brot C, Vestergaard P, Kolthoff N, Gram J, Hermann AP, Sørensen OH. Vitamin D status and its adequacy in healthy Danish perimenopausal women: relationships to dietary intake, sun exposure and serum parathyroid hormone. Br J Nutr. 2001;86(Suppl 1):S97–103.PubMedCrossRefGoogle Scholar
  6. 6.
    Willer CJ, Dyment DA, Sadovnick AD, Rothwell PM, Murray TJ, Ebers GC, et al. Timing of birth and risk of multiple sclerosis: population based study. BMJ. 2005;330:120.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Ebers GC, Sadovnick AD. The geographic distribution of multiple sclerosis: a review. Neuroepidemiology. 1993;12:1–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Burris HH, Rifas-Shiman SL, Huh SY, Kleinman K, Litonjua AA, Oken E, et al. Vitamin D status and hypertensive disorders in pregnancy. Ann Epidemiol. 2014;24(399–403):e1.Google Scholar
  9. 9.
    Bertone-Johnson ER, Hankinson SE, Bendich A, Johnson SR, Willett WC, Manson JE. Calcium and vitamin D intake and risk of incident premenstrual syndrome. Arch Intern Med. 2005;165:1246–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Chan TY. Vitamin D deficiency and susceptibility to tuberculosis. Calcif Tissue Int. 2000;66:476–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Bellamy R. Evidence of gene-environment interaction in development of tuberculosis. The Lancet. 2000;355:588–9.CrossRefGoogle Scholar
  12. 12.
    Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med. 2000;223:230–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr. 2003;89:552–72.PubMedCrossRefGoogle Scholar
  14. 14.
    Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc. 2003;78:1463–70.PubMedCrossRefGoogle Scholar
  15. 15.
    Reichrath J. Vitamin D and the skin: an ancient friend, revisited. Exp Dermatol. 2007;16:618–25.PubMedCrossRefGoogle Scholar
  16. 16.
    Lehmann B, Querings K, Reichrath J. Vitamin D and skin: new aspects for dermatology. Exp Dermatol. 2004;13(Suppl 4):11–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen TC, Chimeh F, Lu Z, Mathieu J, Person KS, Zhang A, et al. Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys. 2007;460:213–7.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr. 2012;95:1357–64.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Lucas RM, Gorman S, Geldenhuys S, Hart PH. Vitamin D and immunity. F1000Prime Rep. 2014;6:118.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Prentice A. Vitamin D deficiency: a global perspective. Nutr Rev. 2008;66:S153–64.PubMedCrossRefGoogle Scholar
  21. 21.
    Hyppönen E, Power C. Hypovitaminosis D in British adults at age 45 y: nationwide cohort study of dietary and lifestyle predictors. Am J Clin Nutr. 2007;85:860–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Rice SA, Carpenter M, Fityan A, Vearncombe LM, Ardern-Jones M, Jackson AA, et al. Limited exposure to ambient ultraviolet radiation and 25-hydroxyvitamin D levels: a systematic review. Br J Dermatol. 2015;172:652–61.PubMedCrossRefGoogle Scholar
  23. 23.
    Cusack C, Danby C, Fallon JC, Ho WL, Murray B, Brady J, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed. 2008;24:260–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Touvier M, Deschasaux M, Montourcy M, Sutton A, Charnaux N, Kesse-Guyot E, et al. Determinants of vitamin D status in Caucasian adults: influence of sun exposure, dietary intake, sociodemographic, lifestyle, anthropometric, and genetic factors. J Invest Dermatol. 2015;135:378–88.PubMedCrossRefGoogle Scholar
  25. 25.
    Gillie O. A new government policy is needed for sunlight and vitamin D. Br J Dermatol. 2006;154:1052–61.PubMedCrossRefGoogle Scholar
  26. 26.
    Major JM, Graubard BI, Dodd KW, Iwan A, Alexander BH, Linet MS, et al. Variability and reproducibility of circulating vitamin D in a nationwide U.S. population. J Clin Endocrinol Metab. 2013;98:97–104.PubMedCrossRefGoogle Scholar
  27. 27.
    Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–81.PubMedCrossRefGoogle Scholar
  28. 28.
    Ezzedine K, Mauger E, Latreille J, Jdid R, Malvy D, Gruber F, et al. Freckles and solar lentigines have different risk factors in Caucasian women. J Eur Acad Dermatol Venereol. 2013;27:e345–56.PubMedCrossRefGoogle Scholar
  29. 29.
    Ezzedine K, Malvy D, Mauger E, Nageotte O, Galan P, Hercberg S, et al. Artificial and natural ultraviolet radiation exposure: beliefs and behaviour of 7200 French adults. J Eur Acad Dermatol Venereol. 2008;22(2):186–94.PubMedGoogle Scholar
  30. 30.
    Felton SJ, Cooke MS, Kift R, Berry JL, Webb AR, Lam PMW, et al. Concurrent beneficial (vitamin D production) and hazardous (cutaneous DNA damage) impact of repeated low-level summer sunlight exposures. Br J Dermatol. 2016;175:1320–8.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Terushkin V, Bender A, Psaty EL, Engelsen O, Wang SQ, Halpern AC. Estimated equivalency of vitamin D production from natural sun exposure versus oral vitamin D supplementation across seasons at two US latitudes. J Am Acad Dermatol. 2010;62:929.e1–9.PubMedGoogle Scholar
  32. 32.
    Wacker M, Holick MF. Sunlight and vitamin D: a global perspective for health. Dermatoendocrinology. 2013;5:51–108.CrossRefGoogle Scholar
  33. 33.
    Rapuri PB, Gallagher JC, Haynatzki G. Effect of vitamins D2 and D3 supplement use on serum 25OHD concentration in elderly women in summer and winter. Calcif Tissue Int. 2004;74:150–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.PubMedCrossRefGoogle Scholar
  36. 36.
    Bischoff-Ferrari HA, Willett WC, Wong JB, Stuck AE, Staehelin HB, Orav EJ, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency. Arch Intern Med. 2009;169:551.PubMedCrossRefGoogle Scholar
  37. 37.
    Ekwaru JP, Zwicker JD, Holick MF, Giovannucci E, Veugelers PJ. The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers. PLoS One. 2014;9:e111265.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Hintzpeter B, Mensink GBM, Thierfelder W, Müller MJ, Scheidt-Nave C. Vitamin D status and health correlates among German adults. Eur J Clin Nutr. 2008;62:1079–89.PubMedCrossRefGoogle Scholar
  39. 39.
    Mithal A, Wahl DA, Bonjour J-P, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20:1807–20.PubMedCrossRefGoogle Scholar
  40. 40.
    Carrillo-Vega MF, García-Peña C, Gutiérrez-Robledo LM, Pérez-Zepeda MU. Vitamin D deficiency in older adults and its associated factors: a cross-sectional analysis of the Mexican Health and Aging Study. Arch Osteoporos. 2017;12:8.PubMedCrossRefGoogle Scholar
  41. 41.
    Greene-Finestone LS, Berger C, de Groh M, Hanley DA, Hidiroglou N, Sarafin K, et al. 25-Hydroxyvitamin D in Canadian adults: biological, environmental, and behavioral correlates. Osteoporos Int. 2011;22:1389–99.PubMedCrossRefGoogle Scholar
  42. 42.
    Daly RM, Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Sikaris KA, et al. Prevalence of vitamin D deficiency and its determinants in Australian adults aged 25 years and older: a national, population-based study. Clin Endocrinol (Oxf). 2012;77:26–35.CrossRefGoogle Scholar
  43. 43.
    Bertrand KA, Giovannucci E, Liu Y, Malspeis S, Eliassen AH, Wu K, et al. Determinants of plasma 25-hydroxyvitamin D and development of prediction models in three US cohorts. Br J Nutr. 2012;108:1889–96.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Thuesen B, Husemoen L, Fenger M, Jakobsen J, Schwarz P, Toft U, et al. Determinants of vitamin D status in a general population of Danish adults. Bone. 2012;50:605–10.PubMedCrossRefGoogle Scholar
  45. 45.
    Engelman CD, Meyers KJ, Iyengar SK, Liu Z, Karki CK, Igo RP, et al. Vitamin D intake and season modify the effects of the GC and CYP2R1 genes on 25-hydroxyvitamin D concentrations. J Nutr. 2013;143:17–26.PubMedCrossRefGoogle Scholar
  46. 46.
    Berger C, Greene-Finestone LS, Langsetmo L, Kreiger N, Joseph L, Kovacs CS, et al. Temporal trends and determinants of longitudinal change in 25-hydroxyvitamin D and parathyroid hormone levels. J Bone Miner Res. 2012;27:1381–9.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Kimlin MG, Lucas RM, Harrison SL, Van Der Mei I, Armstrong BK, Whiteman DC, et al. The contributions of solar ultraviolet radiation exposure and other determinants to serum 25-hydroxyvitamin D concentrations in Australian adults: The AusD study. Am J Epidemiol. 2014;179:864–74.PubMedCrossRefGoogle Scholar
  48. 48.
    Bjørneboe GE, Johnsen J, Bjørneboe A, Rousseau B, Pedersen JI, Norum KR, et al. Effect of alcohol consumption on serum concentration of 25-hydroxyvitamin D3, retinol, and retinol-binding protein. Am J Clin Nutr. 1986;44:678–82.PubMedCrossRefGoogle Scholar
  49. 49.
    Shirazi L, Almquist M, Malm J, Wirfält E, Manjer J. Determinants of serum levels of vitamin D: a study of life-style, menopausal status, dietary intake, serum calcium, and PTH. BMC Women Health. 2013;13:33.CrossRefGoogle Scholar
  50. 50.
    Lee K. Sex-specific relationships between alcohol consumption and vitamin D levels: the Korea National Health and Nutrition Examination Survey 2009. Nutr Res Pract. 2012;6:86–90.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. The Lancet. 2010;376:180–8.CrossRefGoogle Scholar
  52. 52.
    Hiraki LT, Major JM, Chen C, Cornelis MC, Hunter DJ, Rimm EB, et al. Exploring the genetic architecture of circulating 25-hydroxyvitamin D. Genet Epidemiol. 2013;37:92–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Chun RF, Peercy BE, Orwoll ES, Nielson CM, Adams JS, Hewison M. Vitamin D and DBP: the free hormone hypothesis revisited. J. Steroid Biochem. Mol. Biol. 2014;144 Pt A:132–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med. 2013;369:1991–2000.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    McCullough ML, Bostick RM, Mayo TL. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr. 2009;29:111–32.PubMedCrossRefGoogle Scholar
  56. 56.
    Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet. 2010;19:2739–45.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Trummer O, Schwetz V, Walter-Finell D, Lerchbaum E, Renner W, Gugatschka M, et al. Allelic determinants of vitamin d insufficiency, bone mineral density, and bone fractures. J Clin Endocrinol Metab. 2012;97:E1234–40.PubMedCrossRefGoogle Scholar
  58. 58.
    Harris SS, Dawson-Hughes B. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am J Clin Nutr. 1998;67:1232–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Young AR. Some light on the photobiology of vitamin D. J Invest Dermatol. 2010;130:346–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Xiang F, Lucas R, de Gruijl F, Norval M. A systematic review of the influence of skin pigmentation on changes in the concentrations of vitamin D and 25-hydroxyvitamin D in plasma/serum following experimental UV irradiation. Photochem Photobiol Sci. 2015;14:2138–46.PubMedCrossRefGoogle Scholar
  61. 61.
    Batai K, Murphy AB, Shah E, Ruden M, Newsome J, Agate S, et al. Common vitamin D pathway gene variants reveal contrasting effects on serum vitamin D levels in African Americans and European Americans. Hum Genet. 2014;133:1395–405.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Holme SA, Anstey AV, Badminton MN, Elder GH. Serum 25-hydroxyvitamin D in erythropoietic protoporphyria. Br J Dermatol. 2008;159:211–3.PubMedCrossRefGoogle Scholar
  63. 63.
    Mukamel MN, Weisman Y, Somech R, Eisenberg Z, Landman J, Shapira I, et al. Vitamin D deficiency and insufficiency in orthodox and non-orthodox Jewish mothers in Israel. Isr Med Assoc J. 2001;3:419–21.PubMedGoogle Scholar
  64. 64.
    Allali F, El Aichaoui S, Saoud B, Maaroufi H, Abouqal R, Hajjaj-Hassouni N. The impact of clothing style on bone mineral density among post menopausal women in Morocco: a case–control study. BMC Public Health. 2006;6:135.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Ulrich C, Jürgensen JS, Degen A, Hackethal M, Ulrich M, Patel MJ, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case–control study. Br J Dermatol. 2009;161(Suppl 3):78–84.PubMedCrossRefGoogle Scholar
  66. 66.
    Querings K, Girndt M, Geisel J, Georg T, Tilgen W, Reichrath J. 25-Hydroxyvitamin D deficiency in renal transplant recipients. J Clin Endocrinol Metab. 2006;91:526–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Sollitto RB, Kraemer KH, DiGiovanna JJ. Normal vitamin D levels can be maintained despite rigorous photoprotection: six years’ experience with xeroderma pigmentosum. J Am Acad Dermatol. 1997;37:942–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Querings K, Reichrath J. A plea for the analysis of vitamin-D levels in patients under photoprotection, including patients with xeroderma pigmentosum (XP) and basal cell nevus syndrome (BCNS). Cancer Causes Control. 2004;15:219.PubMedCrossRefGoogle Scholar
  69. 69.
    Matsuoka LY, Ide L, Wortsman J, MacLaughlin JA, Holick MF. Sunscreens suppress cutaneous vitamin D3 synthesis. J Clin Endocrinol Metab. 1987;64:1165–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Marks R, Foley PA, Jolley D, Knight KR, Harrison J, Thompson SC. The effect of regular sunscreen use on vitamin D levels in an Australian population. Results of a randomized controlled trial. Arch Dermatol. 1995;131:415–21.PubMedCrossRefGoogle Scholar
  71. 71.
    Farrerons J, Barnadas M, López-Navidad A, Renau A, Rodríguez J, Yoldi B, et al. Sunscreen and risk of osteoporosis in the elderly: a two-year follow-up. Dermatology. 2001;202:27–30.PubMedCrossRefGoogle Scholar
  72. 72.
    Kannan S, Lim HW. Photoprotection and vitamin D: a review. Photodermatol Photoimmunol Photomed. 2014;30:137–45.PubMedCrossRefGoogle Scholar
  73. 73.
    Norval M, Wulf HC. Does chronic sunscreen use reduce vitamin D production to insufficient levels? Br J Dermatol. 2009;161:732–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Vähävihu K, Ala-Houhala M, Peric M, Karisola P, Kautiainen H, Hasan T, et al. Narrowband ultraviolet B treatment improves vitamin D balance and alters antimicrobial peptide expression in skin lesions of psoriasis and atopic dermatitis. Br J Dermatol. 2010;163:321–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Romaní J, Caixàs A, Carrascosa JM, Ribera M, Rigla M, Luelmo J. Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis. Br J Dermatol. 2012;166:1237–44.PubMedCrossRefGoogle Scholar
  76. 76.
    Ryan C, Moran B, McKenna MJ, Murray BF, Brady J, Collins P, et al. The effect of narrowband UV-B treatment for psoriasis on vitamin D status during wintertime in Ireland. Arch Dermatol. 2010;146:836–42.PubMedCrossRefGoogle Scholar
  77. 77.
    Feldmeyer L, Shojaati G, Spanaus K-S, Navarini A, Theler B, Donghi D, et al. Phototherapy with UVB narrowband, UVA/UVBnb, and UVA1 differentially impacts serum 25-hydroxyvitamin-D3. J Am Acad Dermatol. 2013;69:530–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Sehrawat M, Arora TC, Chauhan A, Kar HK, Poonia A, Jairath V. Correlation of vitamin D levels with pigmentation in Vitiligo patients treated with NBUVB therapy. ISRN Dermatol. 2014;2014:493213.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Gruber-Wackernagel A, Obermayer-Pietsch B, Byrne SN, Wolf P. Patients with polymorphic light eruption have decreased serum levels of 25-hydroxyvitamin-D3 that increase upon 311 nm UVB photohardening. Photochem Photobiol Sci. 2012;11:1831–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Barth J, Gerlach B, Knuschke P, Lehmann B. Serum 25(OH)D3 and ultraviolet exposure of residents in an old people’s home in Germany. Photodermatol Photoimmunol Photomed 1992–1993;9:229–31.Google Scholar
  81. 81.
    Karppinen T, Ala-Houhala M, Ylianttila L, Kautiainen H, Viljakainen H, Reunala T, et al. Narrowband ultraviolet B exposures maintain vitamin D levels during winter: a randomized controlled trial. Acta Derm Venereol. 2016;96:490–3.PubMedCrossRefGoogle Scholar
  82. 82.
    Bogh MKB, Gullstrand J, Svensson A, Ljunggren B, Dorkhan M. Narrowband ultraviolet B three times per week is more effective in treating vitamin D deficiency than 1600 IU oral vitamin D3 per day: a randomized clinical trial. Br J Dermatol. 2012;167:625–30.PubMedCrossRefGoogle Scholar
  83. 83.
    Tostmann A, Wielders JPM, Kibiki GS, Verhoef H, Boeree MJ, van der Ven AJAM. Serum 25-hydroxy-vitamin D3 concentrations increase during tuberculosis treatment in Tanzania. Int J Tuberc Lung Dis. 2010;14:1147–52.PubMedGoogle Scholar
  84. 84.
    Joosse A, Koomen ER, Casparie MK, Herings RMC, Guchelaar H-J, Nijsten T. Non-steroidal anti-inflammatory drugs and melanoma risk: large Dutch population-based case–control study. J Invest Dermatol. 2009;129:2620–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014;2:76–89.PubMedCrossRefGoogle Scholar
  86. 86.
    Maghzi H, Ataei B, Khorvash F, Yaran M, Maghzi A-H. Association between acute infectious mononucleosis and vitamin D deficiency. Viral Immunol. 2016;29:398–400.PubMedCrossRefGoogle Scholar
  87. 87.
    Albenali LH, Danby S, Moustafa M, Brown K, Chittock J, Shackley F, et al. Vitamin D and antimicrobial peptide levels in patients with atopic dermatitis and atopic dermatitis complicated by eczema herpeticum: a pilot study. J Allergy Clin Immunol. 2016;138(1715–1719):e4.Google Scholar
  88. 88.
    Abhimanyu A, Coussens AK. The role of UV radiation and vitamin D in the seasonality and outcomes of infectious disease. Photochem Photobiol Sci. 2017;16:314–38.PubMedCrossRefGoogle Scholar
  89. 89.
    Sørensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001;97:3951–9.PubMedCrossRefGoogle Scholar
  90. 90.
    Martineau AR, Newton SM, Wilkinson KA, Kampmann B, Hall BM, Nawroly N, et al. Neutrophil-mediated innate immune resistance to mycobacteria. J Clin Invest. 2007;117:1988–94.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Neville F, Cahuzac M, Konovalov O, Ishitsuka Y, Lee KYC, Kuzmenko I, et al. Lipid headgroup discrimination by antimicrobial peptide LL-37: insight into mechanism of action. Biophys J. 2006;90:1275–87.PubMedCrossRefGoogle Scholar
  92. 92.
    Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, Lowy DR, et al. Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci USA. 2006;103:1516–21.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, et al. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One. 2011;6:e25333.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Campbell GR, Spector SA. Hormonally active vitamin D3 (1alpha,25-dihydroxycholecalciferol) triggers autophagy in human macrophages that inhibits HIV-1 infection. J Biol Chem. 2011;286:18890–902.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Muehleisen B, Bikle DD, Aguilera C, Burton DW, Sen GL, Deftos LJ, et al. PTH/PTHrP and vitamin D control antimicrobial peptide expression and susceptibility to bacterial skin infection. Sci Transl Med. 2012;4:135.CrossRefGoogle Scholar
  96. 96.
    Kota S, Sabbah A, Chang TH, Harnack R, Xiang Y, Meng X, et al. Role of human beta-defensin-2 during tumor necrosis factor-alpha/NF-kappaB-mediated innate antiviral response against human respiratory syncytial virus. J Biol Chem. 2008;283:22417–29.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Quiñones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS. 2000;17:F39–48.CrossRefGoogle Scholar
  98. 98.
    Heine G, Hoefer N, Franke A, Nöthling U, Schumann RR, Hamann L, et al. Association of vitamin D receptor gene polymorphisms with severe atopic dermatitis in adults. Br J Dermatol. 2013;168:855–8.PubMedCrossRefGoogle Scholar
  99. 99.
    Kılıç S, Sılan F, Hız M, Işık S, Ögretmen Z, Özdemir Ö. Vitamin D receptor gene BSMI, FOKI, APAI, and TAQI polymorphisms and the risk of atopic dermatitis. J Investig Allergol Clin Immunol. 2016;26:106–10.PubMedCrossRefGoogle Scholar
  100. 100.
    Weidinger S, Novak N. Atopic dermatitis. The Lancet. 2016;387:1109–22.CrossRefGoogle Scholar
  101. 101.
    Hata TR, Kotol P, Boguniewicz M, Taylor P, Paik A, Jackson M, et al. History of eczema herpeticum is associated with the inability to induce human β-defensin (HBD)-2, HBD-3 and cathelicidin in the skin of patients with atopic dermatitis. Br J Dermatol. 2010;163:659–61.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Camargo CA, Ganmaa D, Sidbury R, Erdenedelger K, Radnaakhand N, Khandsuren B. Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. J Allergy Clin Immunol. 2014;134(831–835):e1.Google Scholar
  103. 103.
    Hata TR, Audish D, Kotol P, Coda A, Kabigting F, Miller J, et al. A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis. J Eur Acad Dermatol Venereol. 2014;28:781–9.PubMedCrossRefGoogle Scholar
  104. 104.
    Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26:662–87.PubMedCrossRefGoogle Scholar
  105. 105.
    Soleymani T, Hung T, Soung J. The role of vitamin D in psoriasis: a review. Int J Dermatol. 2015;54:383–92.PubMedCrossRefGoogle Scholar
  106. 106.
    Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74–84. doi: 10.1016/S0140-6736(14)60763-7.PubMedCrossRefGoogle Scholar
  107. 107.
    Cho S, Kim J, Cho S, Park J, Park Y, Oh S. Vitiligo in children and adolescents: association with thyroid dysfunction. J Eur Acad Dermatol Venereol. 2011;25:64–7.PubMedCrossRefGoogle Scholar
  108. 108.
    Upala S, Sanguankeo A. Low 25-hydroxyvitamin D levels are associated with vitiligo: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. 2016;32:181–90.PubMedCrossRefGoogle Scholar
  109. 109.
    Ezzedine K, Whitton M, Pinart M. Interventions for Vitiligo. JAMA. 2016;316:1708.PubMedCrossRefGoogle Scholar
  110. 110.
    Wu PW, Rhew EY, Dyer AR, Dunlop DD, Langman CB, Price H, et al. 25-Hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum. 2009;61:1387–95.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Mok CC, Birmingham DJ, Ho LY, Hebert LA, Song H, Rovin BH. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus. 2012;21:36–42.PubMedCrossRefGoogle Scholar
  112. 112.
    Amital H, Szekanecz Z, Szücs G, Dankó K, Nagy E, Csépány T, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis. 2010;69(6):1155–7.PubMedCrossRefGoogle Scholar
  113. 113.
    Kamen DL, Aranow C. The link between vitamin D deficiency and systemic lupus erythematosus. Curr Rheumatol Rep. 2008;10:273–80.PubMedCrossRefGoogle Scholar
  114. 114.
    Giles BM, Boackle SA. Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus. Immunol Res. 2013;55:10–21.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Ritterhouse LL, Crowe SR, Niewold TB, Kamen DL, Macwana SR, Roberts VC, et al. Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus. Ann Rheum Dis. 2011;70:1569–74.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Giuggioli D, Colaci M, Cassone G, Fallahi P, Lumetti F, Spinella A, et al. Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature. Clin Rheumatol. 2017;36:583–90.PubMedCrossRefGoogle Scholar
  117. 117.
    Malloy PJ, Feldman D. The role of vitamin D receptor mutations in the development of alopecia. Mol Cell Endocrinol. 2011;347:90–6.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Aksu Cerman A, Sarikaya Solak S, Kivanc Altunay I. Vitamin D deficiency in alopecia areata. Br J Dermatol. 2014;170:1299–304.PubMedCrossRefGoogle Scholar
  119. 119.
    Di Rosa M, Malaguarnera M, Nicoletti F, Malaguarnera L. Vitamin D3: a helpful immuno-modulator. Immunology. 2011;134:123–39.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Ersoy-Evans S. Commentary: vitamin D and autoimmunity: is there an association? J Am Acad Dermatol. 2010;62:942–4.PubMedCrossRefGoogle Scholar
  121. 121.
    Paus R, Bertolini M. The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives. J Investig Dermatol Symp Proc. 2013;16:S25–7.PubMedCrossRefGoogle Scholar
  122. 122.
    Kim DH, Lee JW, Kim IS, Choi SY, Lim YY, Kim HM, et al. Successful treatment of alopecia areata with topical calcipotriol. Ann Dermatol. 2012;24:341–4.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Çerman AA, Solak SS, Altunay İ, Küçükünal NA. Topical calcipotriol therapy for mild-to-moderate alopecia areata: a retrospective study. J Drugs Dermatol. 2015;14:616–20.PubMedGoogle Scholar
  124. 124.
    Gruber-Wackernagel A, Bambach I, Legat FJ, Hofer A, Byrne SN, Quehenberger F, et al. Randomized double-blinded placebo-controlled intra-individual trial on topical treatment with a 1,25-dihydroxyvitamin D3 analogue in polymorphic light eruption. Br J Dermatol. 2011;165:152–63.PubMedCrossRefGoogle Scholar
  125. 125.
    Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–44.PubMedCrossRefGoogle Scholar
  126. 126.
    Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48:155–70.PubMedCrossRefGoogle Scholar
  127. 127.
    Flossmann E, Rothwell PM, British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. The Lancet. 2007;369:1603–13.CrossRefGoogle Scholar
  128. 128.
    Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case–control study. J Invest Dermatol. 2011;131:1460–8.PubMedCrossRefGoogle Scholar
  129. 129.
    Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T. Regulation of terminal differentiation of cultured mouse epidermal cells by l α,25-dihydroxyvitamin D3. Endocrinology. 1983;113:1950–7.PubMedCrossRefGoogle Scholar
  130. 130.
    Bikle DD, Gee E, Pillai S. Regulation of keratinocyte growth, differentiation, and vitamin D metabolism by analogs of 1,25-dihydroxyvitamin D. J Invest Dermatol. 1993;101:713–8.PubMedCrossRefGoogle Scholar
  131. 131.
    Ellison TI, Smith MK, Gilliam AC, MacDonald PN. Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumorigenesis. J Invest Dermatol. 2008;128:2508–17.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Carless MA, Kraska T, Lintell N, Neale RE, Green AC, Griffiths LR. Polymorphisms of the VDR gene are associated with presence of solar keratoses on the skin. Br J Dermatol. 2008;159:804–10.PubMedCrossRefGoogle Scholar
  133. 133.
    Moll PR, Sander V, Frischauf A-M, Richter K. Expression profiling of vitamin D treated primary human keratinocytes. J Cell Biochem. 2007;100:574–92.PubMedCrossRefGoogle Scholar
  134. 134.
    Wong G, Gupta R, Dixon KM, Deo SS, Choong SM, Halliday GM, et al. 1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. J Steroid Biochem Mol Bio. 2004;89–90:567–70.CrossRefGoogle Scholar
  135. 135.
    De Haes P, Garmyn M, Verstuyf A, De Clercq P, Vandewalle M, Degreef H, et al. 1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. J Photochem Photobiol B Biol. 2005;78:141–8.CrossRefGoogle Scholar
  136. 136.
    Mitschele T, Diesel B, Friedrich M, Meineke V, Maas RM, Gärtner BC, et al. Analysis of the vitamin D system in basal cell carcinomas (BCCs). Lab Investig. 2004;84:693–702.PubMedCrossRefGoogle Scholar
  137. 137.
    Bijlsma MF, Spek CA, Zivkovic D, van de Water S, Rezaee F, Peppelenbosch MP. Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLoS Biol. 2006;4:e232.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Eide MJ, Johnson DA, Jacobsen GR, Krajenta RJ, Rao DS, Lim HW, et al. Vitamin D and nonmelanoma skin cancer in a health maintenance organization cohort. Arch. Dermatol. 2011;147:1379.PubMedCrossRefGoogle Scholar
  139. 139.
    Asgari MM, Tang J, Warton ME, Chren M-M, Quesenberry CP, Bikle D, et al. Association of prediagnostic serum vitamin D levels with the development of basal cell carcinoma. J Invest Dermatol. 2010;130:1438–43.PubMedCrossRefGoogle Scholar
  140. 140.
    Tang JY, Parimi N, Wu A, John Boscardin W, Shikany JM, Chren M-M, et al. Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. Cancer Causes Control. 2010;21:387–91.PubMedCrossRefGoogle Scholar
  141. 141.
    Park SM, Li T, Wu S, Li W-Q, Qureshi AA, Cho E. Vitamin D intake and risk of skin cancer in US women and men. PLoS One. 2016;11:e0160308.PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Talpur R, Cox KM, Hu M, Geddes ER, Parker MK, Yang BY, et al. Vitamin D Deficiency in mycosis fungoides and Sézary syndrome patients is similar to other cancer patients. Clin Lymphoma Myeloma Leuk. 2014;14:518–24.PubMedCrossRefGoogle Scholar
  143. 143.
    Rasheed H, Hegazy RA, Gawdat HI, Mehaney DA, Kamel MM, Fawzy MM, et al. Serum vitamin D and vitamin D receptor gene polymorphism in mycosis fungoides patients: a case–control study. PLoS One. 2016;11:e0158014.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115:798–812.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770–3.PubMedCrossRefGoogle Scholar
  146. 146.
    Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2008;159:105–12.PubMedCrossRefGoogle Scholar
  147. 147.
    Orlow I, Roy P, Reiner AS, Yoo S, Patel H, Paine S, et al. Vitamin D receptor polymorphisms in patients with cutaneous melanoma. Int J Cancer. 2012;130:405–18.PubMedCrossRefGoogle Scholar
  148. 148.
    Colston K, Colston MJ, Fieldsteel AH, Feldman D. 1,25-Dihydroxyvitamin D3 receptors in human epithelial cancer cell lines. Cancer Res. 1982;42:856–9.PubMedGoogle Scholar
  149. 149.
    Reichrath J, Rafi L, Rech M, Meineke V, Tilgen W, Seifert M. No evidence for amplification of 25-hydroxyvitamin d-1α-OHase (1α-OHase) or 1,25-dihydroxyvitamin D-24-OHase (24-OHase) genes in malignant melanoma (MM). J Steroid Biochem Mol Biol. 2004;89–90:163–6.PubMedCrossRefGoogle Scholar
  150. 150.
    Yudoh K, Matsuno H, Kimura T. 1alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. J Lab Clin Med. 1999;133:120–8.PubMedCrossRefGoogle Scholar
  151. 151.
    Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang Y-M, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol. 2009;27:5439–44.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Newton-Bishop JA, Davies JR, Latheef F, Randerson-Moor J, Chan M, Gascoyne J, et al. 25-Hydroxyvitamin D2 /D3 levels and factors associated with systemic inflammation and melanoma survival in the Leeds Melanoma Cohort. Int J Cancer. 2015;136:2890–9.PubMedCrossRefGoogle Scholar
  153. 153.
    Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, et al. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res. 2009;29:3669–74.PubMedGoogle Scholar
  154. 154.
    Davies JR, Field S, Randerson-Moor J, Harland M, Kumar R, Anic GM, et al. An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study. Pigment Cell Melanoma Res. 2014;27:234–43.PubMedCrossRefGoogle Scholar
  155. 155.
    Orlow I, Reiner AS, Thomas NE, Roy P, Kanetsky PA, Luo L, et al. Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study. Carcinogenesis. 2016;37:30–8.PubMedCrossRefGoogle Scholar
  156. 156.
    Field S, Davies J, Bishop DT, Newton-Bishop JA. Vitamin D and melanoma. Dermatoendocrinology. 2013;5:121–9.CrossRefGoogle Scholar
  157. 157.
    Randerson-Moor JA, Taylor JC, Elliott F, Chang Y-M, Beswick S, Kukalizch K, et al. Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case–control comparisons and a meta-analysis of published VDR data. Eur J Cancer. 2009;45:3271–81.PubMedPubMedCentralCrossRefGoogle Scholar
  158. 158.
    Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Guerry D, et al. Diet and melanoma in a case–control study. Cancer Epidemiol Biomarkers Prev. 2004;13:1042–51.PubMedGoogle Scholar
  159. 159.
    Veierød MB, Thelle DS, Laake P. Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. Int J Cancer. 1997;71:600–4.PubMedCrossRefGoogle Scholar
  160. 160.
    Miller SA, Coelho SG, Yamaguchi Y, Hearing VJ, Beer JZ, de Gruijl F. The evaluation of non-invasive measurements of erythema as a potential surrogate for DNA damage in repetitively UV-exposed human skin. Photochem Photobiol. 2017;93:1282–8.PubMedCrossRefGoogle Scholar
  161. 161.
    Petersen B, Wulf HC, Triguero-Mas M, Philipsen PA, Thieden E, Olsen P, et al. Sun and ski holidays improve vitamin D status, but are associated with high levels of DNA damage. J Invest Dermatol. 2014;134:2806–13.PubMedCrossRefGoogle Scholar
  162. 162.
    Vieth R. Vitamin D toxicity, policy, and science. J Bone Miner Res. 2007;22(Suppl 2):V64–8.PubMedCrossRefGoogle Scholar
  163. 163.
    Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O’Sullivan MJ, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006;354:684–96.PubMedCrossRefGoogle Scholar
  164. 164.
    Helzlsouer KJ; VDPP Steering Committee. Overview of the cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol. 2010;172:4–9.CrossRefGoogle Scholar
  165. 165.
    Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911–30.PubMedCrossRefGoogle Scholar
  166. 166.
    Bergler-Czop B, Brzezińska-Wcisło L. Serum vitamin D level: the effect on the clinical course of psoriasis. Adv Dermatol Allergol. 2016;6:445–9.CrossRefGoogle Scholar
  167. 167.
    Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, et al. Topical treatments for scalp psoriasis: summary of a cochrane systematic review. Br J Dermatol. 2017;176:604–14.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Department of DermatologyHôpital Henri MondorCréteilFrance
  2. 2.Faculty of MedicineSaint Joseph UniversityBeirutLebanon
  3. 3.EA EpiDermE (Epidémiologie en Dermatologie et Evaluation des Thérapeutiques)UPEC-Université Paris-Est CréteilCréteilFrance

Personalised recommendations